As of 2025-07-05, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (173.52) USD. This relative valuation is based on P/E multiples. With the latest stock price at 39.91 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -534.8%.
The range of the Relative Valuation is (145.91) - (232.06) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.5x - 39.9x | 27.0x |
| Forward P/E multiples | 25.1x - 47.7x | 32.7x |
| Fair Price | (145.91) - (232.06) | (173.52) |
| Upside | -465.6% - -681.5% | -534.8% |
| Date | P/E |
| 2025-07-03 | -6.87 |
| 2025-07-02 | -6.79 |
| 2025-07-01 | -6.24 |
| 2025-06-30 | -6.25 |
| 2025-06-27 | -6.28 |
| 2025-06-26 | -6.39 |
| 2025-06-25 | -6.44 |
| 2025-06-24 | -6.39 |
| 2025-06-23 | -6.34 |
| 2025-06-20 | -6.39 |
| 2025-06-18 | -6.43 |
| 2025-06-17 | -6.31 |
| 2025-06-16 | -6.38 |
| 2025-06-13 | -6.45 |
| 2025-06-12 | -6.76 |
| 2025-06-11 | -6.45 |
| 2025-06-10 | -6.45 |
| 2025-06-09 | -6.37 |
| 2025-06-06 | -6.39 |
| 2025-06-05 | -6.35 |
| 2025-06-04 | -6.30 |
| 2025-06-03 | -6.26 |
| 2025-06-02 | -6.22 |
| 2025-05-30 | -5.85 |
| 2025-05-29 | -6.03 |
| 2025-05-28 | -5.91 |
| 2025-05-27 | -6.03 |
| 2025-05-23 | -6.13 |
| 2025-05-22 | -6.11 |
| 2025-05-21 | -6.09 |
| 2025-05-20 | -6.43 |
| 2025-05-19 | -6.23 |
| 2025-05-16 | -6.13 |
| 2025-05-15 | -5.99 |
| 2025-05-14 | -5.97 |
| 2025-05-13 | -6.09 |
| 2025-05-12 | -6.21 |
| 2025-05-09 | -6.04 |
| 2025-05-08 | -6.19 |
| 2025-05-07 | -5.75 |
| 2025-05-06 | -6.03 |
| 2025-05-05 | -6.69 |
| 2025-05-02 | -6.76 |
| 2025-05-01 | -6.70 |
| 2025-04-30 | -6.71 |
| 2025-04-29 | -6.55 |
| 2025-04-28 | -6.53 |
| 2025-04-25 | -6.55 |
| 2025-04-24 | -6.47 |
| 2025-04-23 | -6.42 |